Sharing this page with your friends could help raise up to 3x more in donations
Oxycodone 15mg requires a valid prescription from a DEA-registered US healthcare provider as a Schedule II controlled substance for moderate-to-severe pain unresponsive to non-opioid therapies; no priority overnight handling or online service can legally dispense it without rigorous medical evaluation, and prescription-free "buy online" constitutes federal felony trafficking under 21 U.S.C. § 841(b), punishable by 5-40 years imprisonment, $5M+ fines, and asset forfeiture.
The 15mg immediate-release strength (acute: 10-15mg q4-6h PRN max 60mg/day opioid-naïve, MME 22.5mg/dose) follows 2025 CDC Guideline 2.0 requiring synchronous HIPAA video confirmation of PEG/BPI ≥7/10 after NSAIDs/acetaminophen failure x7-14 days, PDMP clean, ORT<4 low-risk, universal naloxone co-Rx, and state acute caps (3-7 days/#20-40 tabs)—telemedicine flexibilities end 12/31/2025 with post-2025 in-person mandates and EPCS 2FA; no "handling" overrides REMS or shortages (15% IR Q4).
Pure mu-agonist (Kd 18nM), Tmax 1h IR, t½ 3.5h, F 65%; post-op: 5-15mg q4-6h #48h; chronic: titrate 25% weekly ≤90MME/day; peds ≥11yo tolerant: 0.05-0.15mg/kg q4-6h; contraindications: RR<12, ileus, severe asthma; black box: respiratory/CNS depression, addiction (20-30% chronic), neonatal abstinence—taper 10-25%/week with bowel regimen Day 1.
Pain Quantification: NRS≥6/10 + ODI>20% functional loss.
Video Scrutiny: 30min excluding SOMAT flags, PHQ-4<3.
Protections: PDMP zero recent fills, 1-page contract, CrCl>30.
EPCS Limits: #24 tabs (4 days), zero refills.
CII Chain: Signature 24h tracked.
Vigilance: Day 2 call, q7d x4 (>50% efficacy or taper).
| Rate | Effect | OR | Countermeasure |
|---|---|---|---|
| 20-40% | Nausea (23%), constipation (40%) | Dose | Ondansetron 8mg, PEG BID |
| 10-20% | Somnolence (15%), pruritus (13%) | Elderly x2 | q6h split, Benadryl 25mg |
| 1-10% | Hypotension (5%), retention (3%) | Combo | Orthostatics, tamsulosin |
| <1% | Apnea (0.2%), OD death (0.1%) | Benzos x10 | Naloxone 2mg IN q2min |
OD: naloxone titration (30% resedation); CYP3A4i x3 AUC.
50 states ≤7-day acute/#limited; PDMP AI flags 25% CII; ASHP shortage 15% IR; FDA REMS 80% chronic.
| Tier | Therapy | NNT | Safety |
|---|---|---|---|
| 1 | Ibuprofen 600mg + APAP 1g q6h | 2.4 | <4g APAP |
| 2 | Gabapentin 300mg TID | 3.2 | Renal adjust |
| 3 | Duloxetine 60mg | 4.5 | QT screen |
Legal 15mg overnight no eval? No—CII felony 5-40yrs.
Acute max? 3-7d/#20-40.
Naloxone? Universal CDC ≥50MME.
Shortage? 15% IR Q4 2025.